History · Analysis · No sales, no sourcing

The tanning peptide that never shipped —
and the medicines that did.

Melanotan II was invented to prevent melanoma. It was never approved for anything. It spread through gyms and tanning forums anyway, and two of its side effects became real medicines — neither of them a tan. The founding question is still open: can a drug give human skin lasting protection from the sun, safely?

Start with the timeline →Browse all articles

This is Tan Lines, a publication. We don’t sell Melanotan II, source it, or tell you how to use it. The Record below is the file: where it came from, what the vials actually are, and the drugs that shipped instead.

The mission. Lasting protection from the sun — still unproven, still open.
The gray market. The vials that filled the vacuum when no approved drug came.
The spinoffs. Two approved medicines drawn from its side effects — neither a tan.

Follow a thread

One story in five threads — from the lab that built it to the drug that still hasn’t come.

The mission

The History

Where Melanotan II came from, and what it was actually meant to do.

The sunscreen you'd never have to reapply: where Melanotan came from
Melanotan II began as 1980s melanoma-prevention research at the University of Arizona — an injectable sunscreen. The origin story of the tanning peptide.
Two names on the patent: who owned Melanotan, and how it got loose
How a University of Arizona peptide became two FDA drugs and a gray-market staple: the patent trail from Hruby and Hadley to Clinuvel and Palatin.
How the science escaped the lab: the patents that made a gray market inevitable
Melanotan II's recipe was published in journals and patents, then orphaned by its developers. Public structure plus real demand made the gray market inevitable.
Melanotan I and Melanotan II: one number, two completely different fates
Melanotan I vs Melanotan II: near-identical peptides from the same Arizona lab. One became an approved medicine; the other, the gray market's favorite. Why.
One injection, eight hours, and a second drug hiding inside Melanotan II
A University of Arizona self-experiment with Melanotan II produced an eight-hour erection — and pointed the way to an FDA-approved libido drug.

The mission

The Science

Melanocortin receptors, α-MSH, and how the tanning signal really works.

One hormone, five receptors: why Melanotan II did so much more than tan
Why Melanotan II tans, suppresses appetite, and affects libido at once: one non-selective agonist hitting all five melanocortin receptors.
A drug with no address: the pharmacokinetics of doing everything at once
Why one dose of Melanotan II tans, sickens, and arouses at once: its pharmacokinetics give it no address. It floods the body and outlasts the signal it mimics.
MC1R variants: why the tanning response isn't universal
Red hair is the loud end. Most MC1R variants are quieter: r alleles, heterozygotes, East Asian R163Q. A future agonist would not reach everyone who burns.
How a tan actually protects skin — and why that was the whole idea
A tan is the body's sunscreen: eumelanin absorbing UV before it reaches DNA. How melanin protects skin — and why that was Melanotan's target.
The tan without the sun: what a peptide short-circuits that UV does the hard way
A suntan is a wound response: pigment made only after UV has damaged skin DNA. Melanotan's idea was the protection without the damage.
Why redheads burn: the MC1R gene and the pigment switch
Red hair, freckles, and burning instead of tanning trace to one receptor: MC1R. The keyhole every Melanotan was cut to fit — and a melanoma risk gene.

The gray market

The Demand

Why anyone wanted it in the first place — the reward loop the sun wired in, a century of fashion, and the market that desire built.

How a suntan became desirable
For most of history a tan meant labor; then, in one decade, it flipped. How Chanel, the Riviera, and the sunbed made tanned skin aspirational.
How it's sold now: the market that can't say its own name
Research-chemical storefronts, banned hashtags, influencer commissions, salon shelves, disguised payments — the supply machine that sells Melanotan II now.
Tanorexia: the opioid your skin makes in the sun
UV light makes skin manufacture its own opioid — the hidden reward inside every tan. The science of tanning dependence, and what it says about Melanotan.
The influencer era: how the Barbie drug got re-sold
How Melanotan II went viral: nasal sprays, flavored drops, and the TikTok 'vacation peptide' re-packaged an unregulated injectable for the open market.
Why a cosmetic went underground
Why Melanotan II became the most self-injected unapproved drug: it served a want, not a need — and wants don't wait for clinical trials.

The gray market

The Cautionary Tale

How a lab compound became a gray-market phenomenon, and what it cost.

The Barbie drug: how an unapproved peptide built a global gray market
Never approved anywhere, Melanotan II sold anyway — through forums, gyms, and 'research chemical' sites. How the gray market formed, and what it costs.
What the warnings actually did: a decade of Melanotan II enforcement
Regulators seized sites, parcels, and sellers. Australia made possession a crime. The market moved to nasal sprays. Why enforcement keeps losing.
The mole problem: what dermatologists actually fear about Melanotan II
Melanotan II darkens and multiplies moles — and the deeper danger is diagnostic: the case reports, the melanoma question, and the signals you lose.
The side-effect ledger: what Melanotan II is actually documented to do
Melanotan II side effects, sorted by evidence: the documented acute and pigment effects, and the rare serious events that reach the medical literature.
You can't know what's in the vial
Gray-market Melanotan II comes from unknown labs: purity, sterility, and dose are all assumptions — and assumptions have sent people to the ER.

The spinoffs

The Next Agonist

What it would take for a safe photoprotective drug to reach everyone.

The middle-ground agonist already exists. You just can't have it.
Afamelanotide (Scenesse) is an approved melanocortin drug that protects skin from light — locked in a rare-disease label. Why, and what a breakout would take.
Who would pay for the trial: the sponsor problem
Clinuvel profits from a rare-disease implant. Novo funds prevention trials insurers pay for. A general-public sun drug needs both, and has neither.
The beachhead: the narrow uses that could open the door for everyone
How a photoprotective melanocortin drug could reach everyone: beachhead indications, from approved EPP to a vitiligo trial now in Phase III.
The prevention-trial problem: why 'stops skin cancer' is so hard to prove
Proving a drug prevents skin cancer needs one of the longest, largest trials in medicine. Why the evidence bar — not the chemistry — is the real wall.
The three doors: the U.S. regulatory map for a melanocortin sun drug
Is Melanotan II legal in the U.S.? It's unapproved — but the technology isn't. The three doors: FDA approval, compounding, and the gray market.
What a safe tanning drug would actually have to be
The four requirements a general-public photoprotective drug must clear — and how far today's science already is toward each. Analysis, labeled as such.